Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interventional Radiology for Local Immunotherapy in Oncology.
Tselikas L, Champiat S, Sheth RA, Yevich S, Ammari S, Deschamps F, Farhane S, Roux C, Susini S, Mouraud S, Delpla A, Raoult T, Robert C, Massard C, Barlesi F, Soria JC, Marabelle A, de Baere T. Tselikas L, et al. Among authors: robert c. Clin Cancer Res. 2021 May 15;27(10):2698-2705. doi: 10.1158/1078-0432.CCR-19-4073. Epub 2021 Jan 8. Clin Cancer Res. 2021. PMID: 33419781 Review.
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C. Escudier B, et al. Among authors: robert c. Clin Cancer Res. 2007 Mar 15;13(6):1801-9. doi: 10.1158/1078-0432.CCR-06-1432. Clin Cancer Res. 2007. PMID: 17363536 Clinical Trial.
Cyclophosphamide induces differentiation of Th17 cells in cancer patients.
Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Viaud S, et al. Among authors: robert c. Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9. Cancer Res. 2011. PMID: 21148486 Clinical Trial.
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C. Arnault JP, et al. Among authors: robert c. Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17. Clin Cancer Res. 2012. PMID: 22096025
Targeted therapy-induced radiation recall.
Levy A, Hollebecque A, Bourgier C, Loriot Y, Guigay J, Robert C, Delaloge S, Bahleda R, Massard C, Soria JC, Deutsch E. Levy A, et al. Among authors: robert c. Eur J Cancer. 2013 May;49(7):1662-8. doi: 10.1016/j.ejca.2012.12.009. Epub 2013 Jan 8. Eur J Cancer. 2013. PMID: 23312391
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: robert c. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
Lazar V, Lassau N, Meurice G, Loriot Y, Peña C, Massard C, Robert C, Robert T, Le Berre MA, de Baere T, Dessen P, Soria JC, Armand JP. Lazar V, et al. Among authors: robert c, robert t. Invest New Drugs. 2014 Apr;32(2):312-22. doi: 10.1007/s10637-013-9993-0. Epub 2013 Aug 27. Invest New Drugs. 2014. PMID: 23979492 Clinical Trial.
1,634 results